Association of pain and clinical factors on disability and quality of life in systemic sclerosis: A cross-sectional study from Turkish League Against Rheumatism Network.
Disability
pain
quality of life
systemic sclerosis.
Journal
Archives of rheumatology
ISSN: 2618-6500
Titre abrégé: Arch Rheumatol
Pays: Turkey
ID NLM: 101639000
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
25
09
2021
accepted:
21
12
2021
medline:
26
5
2023
pubmed:
26
5
2023
entrez:
26
5
2023
Statut:
epublish
Résumé
In this study, we aimed to evaluate the factors associated with disability and quality of life (QoL) in Turkish patients with systemic sclerosis (SSc). Between January 2018 and January 2019, a total of 256 SSc patients (20 males, 236 females; mean age: 50.9±12.4 years; range, 19 to 87 years) who were diagnosed with SSc were included in the study. Disability and health-related QoL (HRQoL) were evaluated by the Health Assessment Questionnaire (HAQ), scleroderma HAQ (SHAQ), Duruöz Hand Index (DHI), and Short Form-36 (SF-36). Linear regression analysis methods were used to describe factors associated with disability and QoL of the patients. All disability scores were higher and HRQoL scores were lower in diffuse cutaneous SSc patients compared limited cutaneous SSc, and differentiations were significant (p=0.001 and p=0.007). In multiple regression, pain (VAS) was the strongest predictor for high disability and low QoL scores (p<0.001) as HAQ (β=0.397, 0.386, 0.452), SHAQ (β=0.397, 0.448, 0.372), DHI (β=0.446, 0.536, 0.389), PCS (β=-0.417,-0.499, -0.408) and MCS (β=-0.478, -0.441, -0.370) in combined, lcSSc and dcSSc patients respectively. The factors associated with high disability and low QoL scores were forced vital capacity for HAQ (β=-0.172, p=0.002) and SF-36 PCS (β=0.187, p=0.001); disease duration for HAQ (β=0.208, p<0.001), DHI (β=0.147, p=0.006), and SF-36 PCS (β=-0.134, p=0.014); 6-minute walk test for HAQ (β=-0.161, p=0.005) and SF-36 PCS (β=0.153, p=0.009); and modified Rodnan skin score for SHAQ (β=0.250, p<0.001) and DHI (β=0.233, p<0.001) in SSc patients. Diffusing capacity of the lungs for carbon monoxide for HAQ (β=-0.189, p=0.010) and SHAQ (β=-0.247, p=0.002); erythrocyte sedimentation rate for DHI (β=0.322, p<0.001); age for SF-36 PCS (β=-0.221, p=0.003) and body mass index for SF-36 PCS (β=-0.200, p=0.008) and MCS (β=-0.175, p=0.034) were the other variables associated with high disability or low QoL scores in SSc subsets. Clinicians should consider the management of the pain and its sources as a key to improve better functional state and quality of daily life in SSc.
Identifiants
pubmed: 37235112
doi: 10.46497/ArchRheumatol.2023.9243
pmc: PMC10208607
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9-21Informations de copyright
Copyright © 2023, Turkish League Against Rheumatism.
Déclaration de conflit d'intérêts
Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.
Références
Arthritis Rheum. 1997 Nov;40(11):1984-91
pubmed: 9365087
Pain. 2002 Feb;95(3):267-275
pubmed: 11839426
BMC Res Notes. 2014 Sep 02;7:594
pubmed: 25183055
Clin Exp Rheumatol. 2011 Mar-Apr;29(2 Suppl 65):S53-9
pubmed: 21586219
Arthritis Rheum. 2005 Apr 15;53(2):256-62
pubmed: 15818719
Clin Rheumatol. 2014 Mar;33(3):335-9
pubmed: 24370646
Arch Rheumatol. 2018 Jan 15;33(3):316-321
pubmed: 30632532
Exp Dermatol. 2020 Dec;29(12):1144-1153
pubmed: 32840924
Rheumatology (Oxford). 2018 Feb 1;57(2):370-381
pubmed: 29207002
Arthritis Rheum. 2000 Nov;43(11):2437-44
pubmed: 11083266
Int J Rheum Dis. 2018 Nov;21(11):1884-1893
pubmed: 30428506
Med Care. 1995 Apr;33(4 Suppl):AS264-79
pubmed: 7723455
J Rheumatol. 1988 Feb;15(2):202-5
pubmed: 3361530
Clin Exp Rheumatol. 2018 Jul-Aug;36 Suppl 113(4):3-23
pubmed: 30277868
BMC Musculoskelet Disord. 2017 May 30;18(1):230
pubmed: 28558820
Clin Rheumatol. 2012 Aug;31(8):1215-22
pubmed: 22588647
Arthritis Rheum. 2004 Jun 15;51(3):475-81
pubmed: 15188336
J Rheumatol. 2005 May;32(5):832-40
pubmed: 15868618
Clin Rheumatol. 2005 Feb;24(1):3-10
pubmed: 15674652
Arthritis Rheum. 2004 Oct 15;51(5):805-9
pubmed: 15478150
J Rheumatol. 1996 Jul;23(7):1167-72
pubmed: 8823687
Semin Arthritis Rheum. 2008 Feb;37(4):223-35
pubmed: 17692364
Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7
pubmed: 12091180
Obes Sci Pract. 2018 Jul 25;4(5):417-426
pubmed: 30338112
Arthritis Res Ther. 2019 Feb 15;21(1):61
pubmed: 30770765
Arthritis Rheum. 2009 Mar 15;61(3):400-4
pubmed: 19248123
Arthritis Care Res (Hoboken). 2010 Mar;62(3):409-17
pubmed: 20391488
J Pain Symptom Manage. 2016 Jul;52(1):43-53
pubmed: 26876159
Rheumatology (Oxford). 2018 Sep 1;57(9):1623-1631
pubmed: 29868924
Rheumatology (Oxford). 2018 Mar 1;57(3):441-450
pubmed: 28499034
Rheumatology (Oxford). 2020 Feb 1;59(2):398-406
pubmed: 31359048
Clin Exp Rheumatol. 2019 Jul-Aug;37 Suppl 119(4):3-14
pubmed: 31587697
J Rheumatol. 2006 Jun;33(6):1117-22
pubmed: 16622903
Semin Arthritis Rheum. 2019 Apr;48(5):888-894
pubmed: 30205981
Curr Rheumatol Rep. 2007 May;9(2):151-7
pubmed: 17502046
Rheumatology (Oxford). 2018 Jan 1;57(1):73-83
pubmed: 29155994
Rheumatol Int. 2019 Nov;39(11):1875-1882
pubmed: 31522232
Mod Rheumatol. 2021 May;31(3):657-668
pubmed: 32857628
Rheumatol Int. 2018 Aug;38(8):1471-1478
pubmed: 29497844
Clin Rev Allergy Immunol. 2018 Dec;55(3):312-331
pubmed: 28866756
Ann Rheum Dis. 2013 Nov;72(11):1747-55
pubmed: 24092682
Qual Life Res. 2017 Jan;26(1):85-94
pubmed: 27469505